missing translation for 'onlineSavingsMsg'
Learn More

Invitrogen™ Human Siglec-2 (CD22) His-tag, Recombinant Protein

HEK293 cells Recombinant Protein

79.75 CHF - 275.00 CHF

Spezifikation

Zugriffsnummer P20273
Zur Verwendung mit (Anwendung) Control, ELISA, Immunohistochemistry, Western Blot
Zusammensetzung PBS with 0.02% Tween 80, 5% mannitol, 5% trehalose and no preservative
Gen-ID (Entrez) 933
Name Human Siglec-2 (CD22) His-tag
Mehr Spezifikationen ansehen

Produkte 2
Produktcode Marke Menge Preis Menge & Verfügbarkeit  
Produktcode Marke Menge Preis Menge & Verfügbarkeit  
17174273
Unterlagen ansehen Aktionsdetails
Invitrogen™
A42609
50 μg
275.00 CHF
50 Mikrogramm
Alternative Produkte anzeigen
Sparen Sie bis zu 
»
Verfügbar ab: 07-06-2024
Sie sich ein, um den Lagerbestand zu sehen
Zum Warenkorb hinzufügen
 
17164273
Unterlagen ansehen Aktionsdetails
Invitrogen™
A42608
5 μg
79.75 CHF
5 Mikrogramm
Alternative Produkte anzeigen
Sparen Sie bis zu 
»
Verfügbar ab: 07-06-2024
Sie sich ein, um den Lagerbestand zu sehen
Zum Warenkorb hinzufügen
 
Beschreibung

Beschreibung

CD22 (BL-CAM) is a type 1 integral membrane glycoprotein with molecular weight of 130 to 140 kDa. CD22 is expressed in both the cytoplasm and cell membrane of B-lymphocytes. CD22 antigen appears early in B-cell lymphocyte differentiation at approximately the same stage as the CD19 antigen. Unlike other B-cell markers, CD22 membrane expression is limited to the late differentiation stages comprised between mature B cells (CD22+) and plasma cells (CD22-), and may thus prove useful in phenotyping mature leukemias. CD22 is also strongly expressed in hairy cell leukemia. CD22 preferentially binds to alpha2,6-linked sialic acid. The sialic acid recognition site can be masked by cis interactions with sialic acids on the same cell surface. Upon ligand induced tyrosine phosphorylation in the immune response seems to be involved in regulation of B cell antigen receptor signaling. CD22 plays a role in positive regulation through interaction with Src family tyrosine kinases and may also act as an inhibitory receptor by recruiting cytoplasmic phosphatases via their SH2 domains that block signal transduction through dephosphorylation of signaling molecules. CD22 is also strongly expressed in hairy cell leukemia. CD22 is also positive in diffuse large B-cell lymphoma and nodular lymphocyte predominance Hodgkin’s lymphoma, but negative in classical Hodgkin’s lymphoma.
Spezifikation

Spezifikation

P20273
PBS with 0.02% Tween 80, 5% mannitol, 5% trehalose and no preservative
Human Siglec-2 (CD22) His-tag
-20°C
<1 EU/μg
CD22
Unconjugated
Lyophilized
Control, ELISA, Immunohistochemistry, Western Blot
933
HEK293 cells
RUO
A530093D23; B-cell receptor CD22; BL-CAM; B-lymphocyte cell adhesion molecule; Cd22; CD22 antigen; CD22 molecule; FLJ22814; Leu-14; Lyb8; Lyb-8; MGC130020; sialic acid binding Ig-like lectin 2; sialic acid-binding Ig-like lectin 2; Siglec2; SIGLEC-2; T-cell surface antigen Leu-14
Human
Recombinant
≥ 95%
Videos
Sicherheitsdatenblatt (SDS)
Dokumentation

Dokumentation

Product Certifications